Iovance Biotherapeutics Inc. (IOVA)

19.38
1.60 7.40
NASDAQ : Health Technology
Prev Close 20.94
Open 20.95
Day Low/High 19.35 / 21.17
52 Wk Low/High 7.26 / 26.59
Volume 760.87K
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 123.83M
Market Cap 2.57B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers

With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers

The Seattle firm is selling it three marketed hyperimmune products to Saol Therapeutics. Separately, Aptivo announced the end of its partnership with MorphoSys regarding a potential treatment for prostate cancer.

Iovance Biotherapeutics Becomes Oversold (IOVA)

Iovance Biotherapeutics Becomes Oversold (IOVA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results

Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results

- Company to Host Conference Call at 5:00pm ET Today -